Albireo Pharma
assert phase results summary | Albireo Pharma
Company
Deck Type
Sector
Industry
Deck date
October 2022
Slide
14 of 18
Related slides by other companies
MindMed
Results
May 2022
phase study results key phase study results support progression of into planned upcoming phase clinical program well tolerated up to per day in single ascending dose sad and per day in the multiple ascending dose mad linear maintained across the tested doses and frequencies clinical effects align with potent engagement regimen aligns with preclinical evidence offers potential to be a more effective regimen in withdrawal | MindMed
MindMed
Investor Presentation
June 2023
phase study results key phase study results support progression of results from phase progression of clinical trial demonstrate tolerability and support linear maintained across the tested doses and clinical effects align with potent regimen suitable regimen in withdrawal aligns with preclinical evidence offers potential to be a more frequencies engagement | MindMed
Xeris Biopharma
Investor Presentation
October 2022
topline results of phase study of | Xeris Biopharma
Dare Bioscience
Investor Presentation
February 2023
cream phase ongoing phase clinical study aims to evaluate cream placebo over weeks of dosing following both a non drug and placebo run in period compares cream placebo used in patients home setting primary patient reported outcome pro instruments to measure improvement in localized genital sensations of arousal and reduction in related distress several exploratory efficacy will be measured and could become additional measurements of efficacy in a future phase program topline data of phase respond study targeted for | Dare Bioscience
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights